Paion reports an imminent change in the board: Jürgen Beck, previously responsible for the Remimazolam development program as Chief Development Officer, will leave the company’s board of directors as planned on December 31, 2020, the Aachen-based company announced on Tuesday. CEO Jim Phillips will take over his duties.
In addition, according to Paion, Senior Vice Presidents Shaw Sorooshian (Medical Affairs) and Thomas Stöhr (Development) will lead the market-oriented activities in the field of medical affairs and the remaining development organization, Paion announced. After various approvals for the anesthetic Remimazolam, including in the USA, the company now wants to focus more on product commercialization.
Security data: Paion
Chart analysis tools: click here!
Ticker symbol: PA8
Paion – trade now on: Scalable Personal-Financial.com – Smartbroker – Trade Republic
Tip: Trade and invest better with TradingView charts